Biotech entity

Namit Joshi

Person

All 2 tracked stories fall under one category: pharma. Namit Joshi is most often covered alongside Pharmexcil, which appears in 2 of these 2 stories. Source depth averages 2 original sources per story, versus 2.5 across the same-window beat baseline.

Last mentioned: Aug 12, 2026

Entity pulse

Recent coverage · Namit Joshi

2 stories
6 avg impact
50% positive
50% negative

Coverage balance Balanced directional read. Positive and negative coverage are within 0 percentage points.

  • 50% positive
  • 50% negative

Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.

What the coverage shows about Namit Joshi

All 2 tracked stories fall under one category: pharma. Namit Joshi is most often covered alongside Pharmexcil, which appears in 2 of these 2 stories. Source depth averages 2 original sources per story, versus 2.5 across the same-window beat baseline. The 6 average consequence score is above the beat benchmark of 5.9 in the same window. We currently track 2 Biotech stories that mention Namit Joshi, published between July 27, 2026 and August 1, 2026.

Stories tracked
2
Sources per story
2

Computed from the 2 stories linked to this entity, with beat comparisons drawn from all 50 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.

Coverage cohort

Appears alongside

Other entities that clear the same relevance threshold in stories also covering Namit Joshi. Shared-story counts are live from our verified record — not editorial picks.

Stories mentioning Namit Joshi 2

Pharma Negative

200% US Tariff Threatens Indian Pharma's $50B+ US Generic Business

The proposed US tariff on generic drugs—jumping to 200%—poses an existential threat to Indian pharmaceutical companies that have long dominated the American market. With margins razor-thin and a 4-5 year timeline needed to onshore production, industry leaders call the plan 'completely out of scope,' potentially forcing a major restructuring of global generic supply chains.

2 sources

Source: heraldglobe.com · milwaukeesun.com

Namit Joshi is linked from 2 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.

See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.